Real-World study reveals how breast cancer drugs are actually used in portugal
NCT ID NCT07223476
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at how CDK4/6 inhibitors are used in everyday practice for advanced breast cancer in Portugal. Researchers analyzed data from 16 public hospitals to understand dosing patterns, treatment duration, and how often doses were adjusted. The study included nearly 2,000 patients treated between 2018 and 2023.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib)
What this could lead to
If successful, this study could help doctors understand how these drugs are actually used in clinics, potentially leading to better dosing guidelines and improved patient care.
What could go wrong
This is an observational study using existing data, so it cannot prove cause and effect. Results may not apply to other countries or healthcare systems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States